Table 2.

Associations of APOE2 and APOE4 with neuritic plaque score, AD-tau, and AGD-tau

Variable	APOE2 present		APOE2 absent		Unadjusted analysis		Adjusting for age and sex
	N	Median (minimum, maximum) or No. (%) of subjects	N	Median (minimum, maximum) or No. (%) of subjects	Estimate (95% CI)	P-value	Estimate (95% CI)	P-value
Neuritic plaque score	45		308		0.44 (0.25, 0.78)	0.005	0.49 (0.28, 0.87)	0.015
0		20 (44.4%)		60 (19.5%)
1		4 (8.9%)		62 (20.1%)
2		10 (22.2%)		76 (24.7%)
3		11 (24.4%)		110 (35.7%)
AD-tau	45	16 (35.6%)	302	181 (59.9%)	0.37 (0.19, 0.70)	0.003	0.40 (0.20, 0.78)	0.007
AGD-tau	45	11 (24.4%)	308	40 (13.0%)	2.17 (0.98, 4.51)	0.045	1.89 (0.84, 4.00)	0.11

Variable	APOE4 present		APOE4 absent		Unadjusted analysis		Adjusting for age and sex
	N	Median (minimum, maximum) or No. (%) of subjects	N	Median (minimum, maximum) or No. (%) of subjects	Estimate (95% CI)	P-value	Estimate (95% CI)	P-value
Neuritic plaque score	152		201		5.31 (3.51, 8.05)	< 0.001	4.86 (3.17, 7.46)	< 0.001
0		7 (4.6%)		73 (36.3%)
1		26 (17.1%)		40 (19.9%)
2		37 (24.3%)		49 (24.4%)
3		82 (53.9%)		39 (19.4%)
AD-tau	148	120 (81.1%)	199	77 (38.7%)	6.79 (4.16, 11.36)	< 0.001	6.34 (3.83, 10.76)	< 0.001
AGD-tau	152	13 (8.6%)	201	38 (18.9%)	0.40 (0.20, 0.76)	0.007	0.49 (0.24, 0.95)	0.041

CI Confidence interval. For neuritic plaque score, odds ratios, 95% CIs, and p-values result from proportional odds logistic regression models; odds ratios are interpreted as the multiplicative increase in the odds of a higher neuritic plaque score corresponding to presence of APOE2 or APOE4. For AD-tau and AGD-tau, odds ratios, 95% CIs, and p-value result from binary logistic regression models; odds ratios are interpreted as the multiplicative increase in the odds of the given outcome (AD-tau or AGD-tau) corresponding to presence of APOE2 or APOE4. P-values < 0.0167 were considered as statistically significant after applying a Bonferroni correction for multiple testing; significant findings are shown in bold